Literature DB >> 18548351

Controversies in thyroid pathology: the diagnosis of follicular neoplasms.

Stefano Serra1, Sylvia L Asa.   

Abstract

Thyroid nodules are common; almost 20% of the population has a palpable thyroid nodule and approximately 70% has a nodule detected by ultrasound. Thyroid cancer is the most frequent endocrine malignancy, and incidence rates have steadily increased over the last decades. Papillary carcinoma (PTC) is the most common malignant neoplasm of the thyroid; the diagnosis of this most frequent type (85-90%) has been increasing, possibly due to changing recognition of morphologic criteria. PTC is defined histologically as a malignant tumor showing evidence of follicular epithelial differentiation and characterized by distinctive nuclear features. However, there are borderline lesions that do not completely fulfill these criteria, making the diagnosis difficult. The use of immunohistochemical and molecular markers adds objective criteria to this confusing and controversial area of pathology. We review the differential diagnosis of well-differentiated follicular thyroid neoplasms and the ancillary techniques and molecular characteristics that have been proposed for application in the diagnosis of PTC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18548351     DOI: 10.1007/s12022-008-9031-5

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  59 in total

1.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

Authors:  Y E Nikiforov; J M Rowland; K E Bove; H Monforte-Munoz; J A Fagin
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland.

Authors:  M E DAILEY; S LINDSAY; R SKAHEN
Journal:  AMA Arch Surg       Date:  1955-02

3.  HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.

Authors:  Yasuhiro Ito; Hiroshi Yoshida; Chisato Tomoda; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kennichi Kakudo; Kanji Kuma; Akira Miyauchi
Journal:  Anticancer Res       Date:  2005 Jan-Feb       Impact factor: 2.480

4.  The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions.

Authors:  Gennaro Chiappetta; Paolo Toti; Francesco Cetta; Ada Giuliano; Francesca Pentimalli; Ida Amendola; Stefano Lazzi; Mario Monaco; Luca Mazzuchelli; Piero Tosi; Massimo Santoro; Alfredo Fusco
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

5.  The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.

Authors:  Katie B Weber; Kenneth R Shroyer; David E Heinz; Samia Nawaz; M Sherif Said; Bryan R Haugen
Journal:  Am J Clin Pathol       Date:  2004-10       Impact factor: 2.493

6.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

7.  BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Authors:  Angela M Costa; Agustín Herrero; Manuel F Fresno; Jonas Heymann; José Antonio Alvarez; Jose Cameselle-Teijeiro; Ginesa García-Rostán
Journal:  Clin Endocrinol (Oxf)       Date:  2007-12-05       Impact factor: 3.478

8.  HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm.

Authors:  Takahiro Mase; Hiroomi Funahashi; Takashi Koshikawa; Tsuneo Imai; Yoshiharu Nara; Yuji Tanaka; Akimasa Nakao
Journal:  Endocr J       Date:  2003-04       Impact factor: 2.349

9.  p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Authors:  T Nakamura; I Yana; T Kobayashi; E Shin; K Karakawa; S Fujita; A Miya; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-12

10.  Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis.

Authors:  A Gasbarri; S Sciacchitano; A Marasco; M Papotti; A Di Napoli; A Marzullo; P Yushkov; L Ruco; A Bartolazzi
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more
  10 in total

Review 1.  Advances in metabolomics of thyroid cancer diagnosis and metabolic regulation.

Authors:  Raziyeh Abooshahab; Morteza Gholami; Maryam Sanoie; Fereidoun Azizi; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-04-01       Impact factor: 3.633

Review 2.  Oncocytes, oxyphils, Hürthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules.

Authors:  Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

3.  Follicular adenoma and carcinoma of the thyroid gland.

Authors:  Christopher R McHenry; Roy Phitayakorn
Journal:  Oncologist       Date:  2011-04-11

4.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

5.  Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior.

Authors:  Tijana Isic Dencic; Dubravka Cvejic; Ivan Paunovic; Svetislav Tatic; Marija Havelka; Svetlana Savin
Journal:  Med Oncol       Date:  2012-12-27       Impact factor: 3.064

Review 6.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

7.  Follicular adenomas exhibit a unique metabolic profile. ¹H NMR studies of thyroid lesions.

Authors:  Stanisław Deja; Tomasz Dawiskiba; Waldemar Balcerzak; Magdalena Orczyk-Pawiłowicz; Mateusz Głód; Dorota Pawełka; Piotr Młynarz
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

8.  Serum and urine 1H NMR-based metabolomics in the diagnosis of selected thyroid diseases.

Authors:  Wojciech Wojtowicz; Adam Zabek; Stanislaw Deja; Tomasz Dawiskiba; Dorota Pawelka; Mateusz Glod; Waldemar Balcerzak; Piotr Mlynarz
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

9.  Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.

Authors:  Husain A Saleh; Jining Feng; Farah Tabassum; Opada Al-Zohaili; Muji Husain; Tamara Giorgadze
Journal:  Cytojournal       Date:  2009-09-18       Impact factor: 2.091

Review 10.  A glance at the actual role of glutamine metabolism in thyroid tumorigenesis.

Authors:  Raziyeh Abooshahab; Kourosh Hooshmand; Fatemeh Razavi; Crispin R Dass; Mehdi Hedayati
Journal:  EXCLI J       Date:  2021-07-12       Impact factor: 4.068

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.